|| List of recent Vaccine-related patents
|Toll-like receptor-7 and -8 modulatory 1h imidazoquinoline derived compounds|
The present disclosure provides novel imidazoquinoline derived compounds, derivatives thereof, analogues thereof, and pharmaceutically acceptable salts thereof, and methods of making and using such compounds. The present disclosure also provides tlr7 agonists and tlr7/tlr8 dual agonists, probes, tissue-specific molecules, adjuvants, immunogenic compositions, therapeutic compositions, and self-adjuvanting vaccines including the imidazoquinoline derived compounds, derivatives thereof, analogues thereof, and pharmaceutically acceptable salts thereof.
|Hjurp peptides and vaccines including the same|
Isolated peptides derived from seq id no: 50 and fragments thereof that bind to an hla antigen and induce cytotoxic t lymphocytes (ctl) and thus are suitable for use in cancer immunotherapy are described herein. The inventive peptides encompass both the above mentioned amino acid sequences and modified versions thereof, provided they retain the requisite cytotoxic t cell inducibility of the original sequence.
|Production of avian embryo cells|
The present invention relates to compositions and methods for preparing cells from avian embryos. The invention also relates to cultures of such cells and the uses thereof, particularly for producing viruses such as mdv.
|Synthetic viruses and uses thereof|
The present invention relates to compositions and methods for producing an immune response or reaction, as well as to vaccines, kits, processes, cells and uses thereof. This invention more particularly relates to compositions and methods of using a synthetic viral particle to produce, modify or regulate an immune response in a subject.
|Novel european prrsv strain|
The present invention is related to improved modified live prrs vaccines containing new prrsv european strains of prrsv and methods of use and manufacture of such vaccines.. .
|Virus-like particles and process for preparing same|
An in vitro process of preparing virus-like particles (vlps) from recombinant papaya mosaic virus coat protein and ssrna, which allows for large scale production of vlps in high yields, is provided. Also provided are vlps comprising ssrna prepared by the in vitro process.
|Topk peptides and vaccines including the same|
The present invention provides isolated epitope peptides derived from topk and immunogenic fragments thereof have an ability to induce cytotoxic t lymphocytes (ctls) and thus are suitable for use in cancer immunotherapy, more particularly as cancer vaccines. The peptides of the present invention encompass both of peptides including a topk-derived amino acid sequence and modified versions thereof, in which one, two, or several amino acids are substituted, deleted, inserted and/or added, provided such modified versions have ctl inducibility.
|Dna vaccine, method of inducing the immune response, method of immunisation, antibodies specifically recognising the h5 haemagglutinin of an influenza virus and use of the dna vaccine|
The object of the invention is a dna vaccine, method of inducing the immune response, antibodies specifically recognising the haemagglutinin h5 of an influenza virus and application of the dna vaccine. According to the invention, one or two-fold immunisation of hens with dna vaccine containing a cdna encoding the modified h5 haemagglutinin ha protein, i.e.
|Cross-protective arenavirus vaccines and their method of use|
The invention relates to dna vaccines that target multiple arenavirus agents singly or simultaneously.. .
|Methods for testing an immune response using cultures of t cells, b cells, dendritic cells and follicular dendritic cells|
The present invention relates to methods for preparing an artificial immune system. The artificial immune system comprises a cell culture comprising t cells, b cells and antigen-primed dendritic cells.
|Nanoparticle tumour vaccines|
The present invention provides a vaccine for the prophylactic or therapeutic treatment of a tumour in a mammalian subject, as well as methods of using the vaccine, including in treatment of tumours and in generating a ctl response. The vaccine comprises a plurality of nanoparticles and a pharmaceutically acceptable carrier, salt or diluents.
|Controlled release vaccines and methods for treating brucella diseases and disorders|
Methods and compositions for the treatment of brucella induced diseases and disorders are disclosed herein. In preferred embodiments, the invention relates to vaccines.
|Liposomal vaccine compositions comprising a polysaccharide antigen and a protein adjuvant|
A liposomal composition, preferably a vaccine, comprising liposomes formed of liposome forming compounds, containing coentrapped polysaccharide antigen and t-cell dependent protein carrier, such as tetanus toxoid or diphtheria toxin modified to render it non-toxic. The invention is of use in the production of vaccines against haemophilus influenzae, streptococcus pneumoniae or neisseria meningitidis..
|Adjuvanted influenza b virus vaccines for pediatric priming|
The influenza b strain is epidemiologically relevant in the pediatric population. Immunogenic priming of children with influenza b vaccine adjuvanted with an oil-in-water emulsion primes an immune response to a booster vaccine comprising influenza b virus antigen from a different strain or lineage, irrespective of whether the booster comprises an adjuvant..
|Influenza vaccines including combinations of particulate adjuvants and immunopotentiators|
Influenza vaccines containing insoluble particulate adjuvants have been found to elicit an igg response that is primarily a th2 response (igg1). This response can be shifted towards a th1 response (igg2a) by including immunopotentiators in the compositions.
|Cationic metal oxides for use as vaccine adjuvants|
Adjuvant and immunological vaccine compositions comprising modified, cationic metal oxides are disclosed, including methods of making modified, cationic metal oxides and methods of using the modified metal oxides in vaccine formulations and regimens.. .
|Dna promoters and anthrax vaccines|
The invention is related to intracellularly induced bacterial dna promoters and vaccines against bacillus anthracis.. .
|Adenoviral vectors comprising partial deletions of e3|
This disclosure provides replication-incompetent adenoviral vectors useful in vaccine development and gene therapy. The disclosed vectors comprise a selective deletion of e3 and are particularly useful for preparation of vaccines development and for gene therapy using toxic transgene products that result in vector instability that occurs when the entire e3 domain is deleted..
|Synthetic streptococcus pneumoniae vaccine|
Compositions and methods for preventing and treating pneumococcal infections are provided. Compositions include novel polypeptides comprising an amino acid sequence corresponding to the r21 or r22 domain of cbpa or a consensus sequence of one of these domains, and variants and fragments thereof, wherein the polypeptide is stabilized in a desired conformation, particularly a loop conformation.
|Peptide vaccines for cancers expressing tumor-associated antigens|
The present invention provides peptides having an amino acid sequence as set forth in seq id no: 19, 22, 30, 34, 344, 358, 41, 44, 46, 48, 78, 376, 379, 80, 100, 101, 110, 111, 387, 112, 394, 114, 116, 117, 121, 395, 133, 135, 137, 426, 143, 147, 148, 149, 150, 152, 153, 154, 156, 160, 161, 162, 163, 166, 174, 178, 186, 194, 196, 202, 210, 213, 214, 217, 223, 227, 228, 233, 254, 271, 272 or 288, as well as peptides having the above-mentioned amino acid sequences in which 1, 2, or several (e.g., up to 5) amino acids are substituted, deleted, or added, provided the peptides possess cytotoxic t cell inducibility. The present invention also provides drugs for treating or preventing a disease associated with over-expression of the cdh3, epha4, ect2, hig2, inhbb, kif20a, kntc2, ttk and/or urlc10, e.g.
|Vaccine based on staphylococcal superantigen-like 3 protein (ssl3)|
The present invention relates to the field of vaccinology, especially of vaccines against staphylococcus aureus, for both human and veterinary application. In particular the invention relates to a staphylococcal superantigen-like 3 (ssl3) protein or its homolog, an immunogenic fragment of either protein, for use in a vaccine against s.
|Recombinant proteins for use in vaccine, antibodies against said proteins, and diagnostic and therapeutic methods including the same|
The present invention relates to proteins and/or fragments and derivatives thereof and their use as vaccines and in biotechnological methods. The vaccines particularly include immunogenic proteins in treponema spp.
|Method of treating cancer|
The invention provides a method for treating cancer using a coadministration strategy that combines local codelivery of a therapeutic agent and an intracellular penetration enhancing agent, and optionally in further combination with local administration of an immunotherapeutic agent, such as a cancer vaccine or nkt agonist. The invention also provides a method for treating cancer using an intracellular penetration enhancing agent.
|Production of infectious rna viruses in yeast|
The method described herein provides a novel platform utilizing yeast as a biological non-host system to express and assemble whole viruses for use as attenuated or killed vaccines.. .
|Inactivating pathogens with oxidizing agents for vaccine production|
The present disclosure provides methods for producing a vaccine composition containing a pathogen that is rendered noninfectious by exposure to hydrogen peroxide. The methods disclosed herein are suitable for the preparation of vaccines for a wide variety of pathogens, including viruses, bacteria and parasites.
|Cdna construct of salmonidae alphavirus|
The invention concerns recombinant dna's comprising cdna of genomic rna of a salmonidae alphavirus preceded by a spacer sequence, under the control of a suitable promoter. Said recombinant dnas are useful for obtaining expression vectors, producing recombinant salmonidae alphavirus, and for obtaining vaccines..
|Liquid vaccine preparations|
This document provides methods and materials involved in making and using liquid vaccine preparations for oral administration. For example, methods and materials for making and using liquid vaccine preparations for oral administration that include a lyophilized or dried vaccine component (e.g., a lyophilized pathogenic agent such as a lyophilized rotavirus preparation) and a liquid edible oil composition (e.g., a liquid edible oil composition containing one or more medium chain triglycerides) are provided.
|Staphylococcus aureus proteins and nucleic acids|
The invention provides proteins from staphylococcus aureus including amino acid sequences and the corresponding nucleotide sequences. The proteins are useful for vaccines, immunogenic compositions, diagnostics, enzymatic studies and also as targets for antibiotics..
|Vaccines for chlamydia|
The present invention relates to means and methods to protect against disease caused by bacteria belonging to the genus chlamydia. In particular, the present invention relates to isolated b- and t-cell epitopes derived from the major outer membrane protein of chlamydia psittaci which can be used against an infection with a species of the genus chlamydia.
|Self-assembling peptide nanoparticles as vaccines against infection with norovirus|
Self-assembling peptide nanoparticles (sapn) incorporating t-cell epitopes and displaying the p domain of the norovirus protein vp1 are described. The nanoparticles of the invention consist of aggregates of a continuous peptide chain comprising two coiled coil oligomerization domains connected by a linker segment wherein one or both oligomerization domains incorporate t-cell epitopes within their peptide sequence.
|Influenza hemagglutinin and neuraminidase variants|
Polypeptides, polynucleotides, methods, compositions, and vaccines comprising influenza hemagglutinin and neuraminidase variants are provided.. .
|Immunologic constructs and methods|
The present invention relates to improved vaccines and the design and making of such vaccines that enhance immunogenicity of the vaccine and/or reduce reactogenicity to the vaccine when administered. In particular the vaccines and immunogenic compositions of the present invention relate to flagellin-antigen fusion proteins in which the spatial orientation of the flagellin to antigen and the charge distribution of the antigen is optimized to enhance immunogenicity and/or reduce reactogenicity and/or improve folding of the protein..
|Methods of promoting immune tolerance|
Compositions including a polynucleotide combined with a vehicle and methods of their use to induce a suppressive immune response are provided. In some embodiments the compositions induce an increase in expression of indoleamine 2,3 dioxygenase (ido) enzyme activity in cells.
|Novel vlps derived from cells that do not express a viral matrix or core protein|
The present invention discloses novel influenza virus-like particles (vlps) that contain chimeric proteins or influenza membrane proteins. The chimeric proteins are derived from fragments of influenza membrane proteins fused to heterologous proteins.
|Total synthesis and immunological evaluation of saccharide moieties of the lipopolysaccharide from neisseria meningitidis|
The present invention relates to the total chemical synthesis of the monosaccharide 35# (r′═h), the disaccharide 36# (r′≠h; r″═h), the trisaccharide 37# (r′≠h; r″≠h; r′″≠h) and the tetrasaccharide 1# (r′≠h; r″≠h; r′″≠h) of the following general formula wherein r represents —y—nh2y represents a linker r′ is h or r″ is h or r′″ is h or of the lipopolysaccharide from neisseria meningitidis, as well as to the trisaccharide 37# and the tetrasaccharide 1#, to vaccines containing at least one of the saccharides 1#, 35#, 36#, and 37# and to the use of such vaccine for immunization against diseases caused by infection with bacteria containing the tetrasaccharide α-glcnac-(1→2)-α-hep-(1→3)-α-hep-(1→5)-α-kdo or the trisaccharide α-hep-(1→3)-α-hep-(1→5)-α-kdo or α-glcnac-(1→2)-α-hep-(1→3)-α-hep, especially for immunization against meningitis, septicaemia, pneumonia and nasopharyngitis caused by neisseria meningitidis.. .
Disclosed are immunogenic conjugates having the general formula: ha2-xxx-pr, where ha2 is the influenza ha2 fusion peptide or a portion thereof, xxx is a linker and pr is the carrier. Methods of producing an immune response in a subject using the disclosed immunogenic conjugates, as well as methods of treating, ameliorating or preventing influenza infection, are also disclosed..
|Plant viral vaccines and therapeutics|
The invention relates to methods and related products for preventing and treating disease, based on the use of plant viral vaccines and plant viral defense strategies. The methods also involve the identification of appropriate therapeutic strategies for diseases such as cancers..
|Newcastle disease virus vectored avian vaccines|
The present invention encompasses engineered newcastle disease virus (ndv) vaccines or compositions. The vaccine or composition may be a recombinant vaccine.
|Influenza antigen delivery vectors and constructs|
The present invention relates to fluorocarbon vectors for the delivery of influenza antigens to immunoresponsive target cells. It further relates to fluorocarbon vector-influenza antigen constructs and the use of such vectors associated with antigens as vaccines and immunotherapeutics in animals, including humans..
|Infectious clones of torque teno virus|
The present invention is directed to novel nucleotide and amino acid sequences of torque teno virus (“ttv”), including novel genotypes thereof, all of which are useful in the preparation of vaccines for treating and preventing diseases in swine and other animals. Vaccines provided according to the practice of the invention are effective against multiple swine ttv genotypes and isolates.
|Porcine parvovirus 5b, methods of use and vaccine|
The present invention provides novel nucleotides sequences, protein sequences, immunogenic compositions, vaccines, and methods that relate to making and using new porcine parvovirus 5b (ppv5b) that infects, inter alia, domestic swine. The compositions and methods provide for the detection of infections by said new virus, monitoring genetic changes in the viral sequences in wild and domestic animals and herds, and making and using novel vaccines for protecting animals from infection by the virus..
|Cancer vaccines and vaccination methods|
Compositions of multipeptide vaccines comprising at least seven tumor associated antigens, compositions of antigen presenting cell (e.g., dendritic cell) based vaccines presenting epitopes from at least seven tumor associated antigens, and methods of making same, are provided herein. Also, disclosed are methods for treating gynecological and peritoneal cancers using such vaccines..
|Ovarian cancer vaccines and vaccination methods|
Compositions of multipeptide vaccines including tumor associated antigens, compositions of antigen presenting cell (e.g., dendritic cell) based vaccines presenting epitopes from tumor associated antigens, and methods of making same, are provided herein. Also, disclosed are methods for treating ovarian cancers using such vaccines..
|Nanoparticles, process for preparation and use thereof as carrier for amphipatic and hydrophobic molecules in fields of medicine including cancer treatment and food related compounds|
The present invention regards nanoparticles comprising a sterol and a component derived from quillaja saponaria molina selected from quillaja acid and quillaja saponin, which nanoparticles do not comprise a phospholipid. It also relates to a composition comprising the nanoparticles, and the use thereof as adjuvant, especially in vaccines, as carriers for amphipathic or hydrophobic molecules and as agents for treatment of cancer.
|Anti-cd40 antibodies and uses thereof|
The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccines and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-cd40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-cd40 antibody or fragments thereof, including humanized antibodies..
|Tumor specific oligosaccharide epitopes and use thereof|
The present invention describes oligosaccharide sequences, which are specifically expressed by human tumors. The present invention is related to a method of determining an oligosaccharide sequence, which comprises a tumor specific terminal n-acetylglucosamine residue, in a biological sample, the presence of said sequence in said sample being an indication of the presence of cancer.
|Retroviral vector particles and methods for their generation and use|
The present invention relates to methods of host cell transduction utilising ecotropic retroviral vector particles. The retroviral vector particle may comprise an envelope of friend murine leukaemia virus, in particular the envelope encoded by molecular clone pvc-211 and the host cell may be engineered to recombinantly express the rec1 receptor.
|Biological systems for production of highest quality proteins|
Vaccines and therapeutic proteins, including polyclonal and monoclonal antibodies, must be maximally pure and stable in their most active native form. This is a requirement for their maximal efficacy, specificity and stability as well as for precluding immune responses against erroneous or damaged moieties.
|Engineered type iv pilin of clostridium difficile|
The present invention relates to engineered clostridium difficile type iv pilin (tfp) genes, type iv pilin proteins which can serve as a diagnostic marker for identification of patients infected with c. Difficile, and vaccines comprising type iv pilin proteins, antigenic fragments and variants thereof for therapeutic interventions..
|A1 moiety of cholera toxin a subunit as an adjuvant for mucosal and systemic vaccines|
The present invention relates to cholera toxin cta1 protein fragments, adjuvant compositions, and methods relating to adjuvants for vaccines. The invention also relates to using recombinant cta1 fragments conjugated to a polypeptide containing a protein transduction domain or cell-penetrating peptide as an immunomodulator..
|Method for removing immunosuppressive properties of hiv envelope glycoproteins|
The present invention concerns a method for removal of immunosuppressive effects of envelope glycoproteins derived from human immunodeficiency virus, such as for vaccination purposes and for generation of neutralizing antibodies to hiv. The invention further concerns vaccines and antibodies obtainable by the method, as well as the use of such vaccines and antibodies..
|Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response|
Herpes simplex virus-2 (hsv-2) infection is a major health concern. The present disclosure provides, inter alia, certain highly effective vaccines and immunogenic compositions against hsv-2.
|Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines|
The present invention relates to use of multimeric multi-epitope peptide-based compositions for immunizing subjects against influenza by administering the compositions to the subject prior to or together with seasonal or pandemic influenza vaccines. The present invention also relates to compositions that include a multimeric multi-epitope polypeptide and a seasonal or pandemic preparation against influenza..
|Vaccines for preventing and treating alzheimer's disease|
Disclosed herein are vaccines comprising an amyloid beta antigen and a nucleic acid encoding the amyloid beta antigen, or a variant thereof. T cell proliferation can be inhibited and itreg cells can be stimulated in the subject administered the vaccine.
|Glutathione-based drug delivery system|
The invention relates to methods of targeted drug delivery of compounds, including, chemical agents, (poly)peptides and nucleic acid based drugs (like dna vaccines, antisense oligonucleotides, ribozymes, catalytic dna (dnazymes) or rna molecules, sirnas or plasmids encoding thereof). Furthermore, the invention relates to targeted drug delivery of compounds to extravascular and intracellular target sites within cells, tissues and organs, in particular to target sites within the central nervous system (cns), into and across the blood-brain barrier, by targeting to glutathione transporters present on these cells, tissues and organs.
|Decorated macromolecular scaffolds|
The present invention relates to a method for preparing decorated macromolecular scaffolds. The method of the invention is useful for the generation of bioactive nanoparticles for use in clinical applications.
|Platform of dendritic cell (dc)-based vaccination|
The present invention discloses novel dendritic cell maturation-inducing cytokine cocktails, and methods for inducting type-1 polarized dendritic cells in serum-free conditions which enhance the desirable properties of dc1s generated in serum-supplemented cultures. The invention further discloses methods and systems using ifnγ and other ligands of the ifnγ receptor, in combination with ifnα (or other type i interferons), poly i:c, and other ifnα (and ifnβ) inducers to enhance the il-12-producing properties of dendritic cells.
|Live bacterial vaccines for prophylaxis or treatment of infection|
A live bacterium, having a dna construct stabilized against transduction of other bacteria, having a promoter sequence and encoding a fusion peptide, comprising a bacterial secretion peptide portion and a non-bacterial immunogenic polypeptide portion, having a nucleotide sequence coding for the non-bacterial immunogenic polypeptide portion which has at least one codon optimized for bacterial expression. The bacterium has a secretion mechanism which interacts with at least the bacterial secretion peptide portion to cause a secretion of the fusion peptide from the bacterium, and a genetic virulence attenuating mutation.
|Proteins expressed by mycobacterium tuberculosis and not by bcg and their use as diagnostic reagents and vaccines|
The present invention is directed to reagents useful for generating immune responses to mycobacterium tuberculosis and for diagnosing infection and disease in a subject that has been exposed to m. Tuberculosis..
|Truncated hiv envelope proteins (env), methods and compositions related thereto|
The instant application provides methods and related compositions pertaining to novel hiv envelope proteins. In some embodiments, the invention relates to methods and compositions for the preparation, production, and administration of isolated novel hiv envelope nucleic acid and protein sequences suitable, for example, as vaccines against hiv..
|Tape preparation of wt1 peptide cancer vaccine for transdermal administration|
(ii) a first cellular immunity induction promoter. The tape preparation can provides high efficacy..
|Vaccine composition for transdermal administration|
The invention provides a cancer vaccine composition for transdermal administration for inducing cellular immunity comprising (i) her2/neu e75 peptide and/or a modified her2/neu e75 peptide; and (ii) a first cellular immunity induction promoter.. .
|Cationic oil-in-water emulsions|
This invention generally relates to cationic oil-in-water emulsions that contain high concentrations of cationic lipids and have a defined oil:lipid ratio. The cationic lipid can interact with the negatively charged molecule thereby anchoring the molecule to the emulsion particles.
|Vaccine composition for mucosal administration|
The present invention provides a cancer vaccine composition for mucosal administration comprising (i) a her2/neu e75 peptide and/or a modified her2/neu e75 peptide; and (ii) a first cellular immunity induction promoter.. .
|New modified live flavobacterium strains, stabilized vaccines comprising same, and methods of making and use thereof|
The present invention provides attenuated f. Columnare strains that elicit an immune response in an animal, particularly a fish, against virulent f.
|Recombinant mistletoe lectin and use thereof as an adjuvant|
The invention relates to vaccines that comprise antigens and an adjuvant, and to the use of the adjuvant, wherein the adjuvant is selected from a recombinant mistletoe lectin.. .
|Multi plasmid system for the production of influenza virus|
Vectors and methods for the production of influenza viruses suitable as recombinant influenza vaccines in cell culture are provided. Bi-directional expression vectors for use in a multi-plasmid influenza virus expression system are provided..
|Wt1 peptide cancer vaccine composition for mucosal administration|
The present invention provides a cancer vaccine composition for mucosal administration for inducing cellular immunity, comprising (i) a wt1 peptide and/or a modified wt1 peptide; and (ii) a cellular immunity induction promoter. The composition efficiently induces cellular immunity against a cancer in a subject..
|Wt1 peptide cancer vaccine composition for transdermal administration|
The present invention provides a cancer vaccine composition for transdermal administration for cellular immunity induction, comprising (i) a wt1 peptide and/or a modified wt1 peptide; and (ii) a pharmacologically acceptable acid as a first cellular immunity induction promoter, or a pharmacologically acceptable salt thereof.. .
|Wt1 peptide cancer vaccine composition for transdermal administration|
The present invention provides a cancer vaccine composition for transdermal administration for inducing cellular immunity, comprising (i) a wt1 peptide and/or a modified wt1 peptide; and (ii) a cellular immunity induction promoter. The composition efficiently induces cellular immunity against a cancer in a subject..